MENS Stock Analysis: Buy, Sell, or Hold?
MENS - Jyong Biotech Ltd. Ordinary Shares
$1.74
-0.15 (-7.94%)
▼
5d:
-12.12%
30d:
-18.69%
90d:
-26.27%
WAIT
LOW Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Aug 13, 2026
0d
Get Alerted When MENS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: MENS is down 12.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: MENS is down 12.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: MENS is currently trading at $1.74, which is considered oversold relative to its 30-day fair value range of $1.93 to $2.16.
Technical Outlook: Technically, MENS is showing sideways momentum. Immediate support is located at $1.64, while resistance sits at $2.18. Short-term momentum is weak, with the stock down 7.9% recently.
Market Sentiment: MENS scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, MENS is showing sideways momentum. Immediate support is located at $1.64, while resistance sits at $2.18. Short-term momentum is weak, with the stock down 7.9% recently.
Market Sentiment: MENS scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.93 -
$2.16
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
47.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (33/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-7.9%)
- WARNING: Composite score 44/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.93 -
$2.16
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.64
Resistance Level
$2.18
Current Trend
Sideways
Technical data as of
Oct 22, 2026
Fundamental Context
Share & Embed Analysis
Last updated: October 23, 2026 7:47 AM ET
Data refreshes hourly during market hours. Next update: 8:47 AM
Data refreshes hourly during market hours. Next update: 8:47 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MENS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
STRONG BUY
25 analysts |
$84 | 58 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 50 HOLD |
|
JANX
Janux Therapeutics Inc |
STRONG BUY
18 analysts |
$36 | 49 HOLD |
|
TSHA
Taysha Gene Therapies Inc |
STRONG BUY
13 analysts |
$13 | 61 BUY |
|
TRVI
Trevi Therapeutics Inc |
STRONG BUY
11 analysts |
$28 | 69 BUY |